Fine chemical

Burcon Successfully Scales Commercial Production of 95% Hempseed Protein Isolate

Retrieved on: 
Monday, March 25, 2024
HPS, TSX, Drink, Fine chemical

Burcon has achieved a significant milestone with the successful scale-up of its groundbreaking hempseed protein isolate at its partner manufacturer's production facility.

Key Points: 
  • Burcon has achieved a significant milestone with the successful scale-up of its groundbreaking hempseed protein isolate at its partner manufacturer's production facility.
  • From its production runs, Burcon produced high-quality, commercial saleable quantities of its 95% hempseed protein isolate to fulfill initial customer orders.
  • Anticipated commercial sales and further production campaigns of Burcon's hempseed protein are slated for the first half of 2024 to meet growing customer demand.
  • "We believe that the 95% hempseed protein isolate is a game changer that can tap into a burgeoning hemp foods market.

Cambridge Isotope Laboratories, Inc. (CIL) Announces Relocation of Corporate Headquarters and Expansion of Research & Development and cGMP Production

Retrieved on: 
Friday, March 15, 2024
CIL, GMP, CSO, QC, CGMP, Isotope, Research, Growth, API, Fine chemical

The new location is a two-building, 150,000-square-foot campus with 25 lakefront acres at 100 & 200 Ames Pond Drive.

Key Points: 
  • The new location is a two-building, 150,000-square-foot campus with 25 lakefront acres at 100 & 200 Ames Pond Drive.
  • The Ames Pond campus will be the home of a new 8,000-square-foot research and development (R&D) facility and will significantly expand cGMP, QC, formulations, and production labs.
  • This expansion provides CIL the space to develop new products and invest in advanced analytical and production technologies," states CIL's Chief Science Officer (CSO) Todd Osiek.
  • CIL will continue operating its existing headquarters at 3 Highwood Drive, Tewksbury, MA, and production facility located 50 Frontage Road in Andover, MA.

MEF Pioneers Industry Leading Enterprise Business and Operational LSO API Portfolio for Network Services

Retrieved on: 
Tuesday, April 9, 2024
Automation, SD-WAN, Growth, ELC, Verizon Business, Internet of things, LSO, AI, Carrier Ethernet, Network as a service, Ecosystem, API, GNE, Zero trust security model, Chair, MEF, Fine chemical

LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- MEF , a global industry association of network, cloud, security, and technology providers accelerating enterprise digital transformation, today announced availability of its MEF enterprise business and operational Lifecycle Service Orchestration (LSO) API portfolio .

Key Points: 
  • LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- MEF , a global industry association of network, cloud, security, and technology providers accelerating enterprise digital transformation, today announced availability of its MEF enterprise business and operational Lifecycle Service Orchestration (LSO) API portfolio .
  • "MEF’s enterprise business and operational LSO API portfolio is a game-changer for enterprises undergoing digital transformation," said Debika Bhattacharya, Chair, MEF Board of Directors, and Chief Technology Solutions Officer, Verizon Business.
  • The MEF enterprise business and operational LSO API portfolio enables service providers to use the same APIs that automate business and operational functions between service providers to automate similar functions between service providers and enterprises for subscriber services, thereby streamlining enterprise digital transformation.
  • MEF enterprise business and operational LSO APIs are available for Carrier Ethernet (E-Line, E-LAN and E-Tree) and traditional IP Broadband and Direct Internet Access network services.

Wyss Institute’s AminoX project receives funding from Northpond Labs to accelerate innovation in protein-based therapeutics

Retrieved on: 
Monday, April 8, 2024
Molecule, Research, Innovation, Patient, DNA, Wyss Institute, Engineering, Protein, Laboratory, Organic acid, Harvard University, CRISPR, Drug development, Wyss, Biological engineering, Therapy, Genetic code, FDA, Antiandrogen, Vocabulary, Fine chemical

This is the fourth Wyss project selected by Northpond Labs for additional funding.

Key Points: 
  • This is the fourth Wyss project selected by Northpond Labs for additional funding.
  • The Laboratory has previously funded the Wyss’ eRNA (now being commercialized by EnPlusOne Biosciences ), SomaCode , and Lab-on-a-Molecule projects.
  • “The AminoX platform has the potential to transform our ability to develop differentiated protein-based therapeutics by significantly expanding the vocabulary of building blocks that can be incorporated into biologics at high throughput.
  • We are thrilled that the AminoX team’s journey to the market will be accelerated by this support,” said Angelika Fretzen, Ph.D., M.B.A., the Wyss Institute’s Technology Translation Director & Chief Operating Officer.

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

Retrieved on: 
Friday, April 5, 2024
TME, Development, FAP, Doctor of Philosophy, Patient, Doxorubicin, Tumor microenvironment, Royal Marsden Hospital, MD, AACR, Research and development, Institute of Cancer Research, Poster, Heterotrimeric G protein, BST, AIM, Fine chemical

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

Key Points: 
  • Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
  • A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/ .
  • Christina Coughlin will provide a video presentation overview examining the data presented in the poster.
  • Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data.

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

Retrieved on: 
Thursday, April 4, 2024
Acumen, Patient, CGMP, Penile spines, Fine chemical

The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization, if approved.

Key Points: 
  • The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization, if approved.
  • Under the terms of the agreement, Lonza will manufacture the sabirnetug drug substance at its next-generation, manufacturing facility in Portsmouth, New Hampshire (US), equipped with 2,000L single-use bioreactors.
  • Acumen will leverage Lonza’s regulatory expertise, extensive experience in antibody manufacturing, and global manufacturing network from 2,000L to 20,000L.
  • Sabirnetug is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs in a Phase 1 first-in-human study.

Nxera Pharma is the New Name for Sosei Group

Retrieved on: 
Monday, April 1, 2024
Health, Growth, Neurology, Science, Patient, DSM-IV codes, GI, Therapy, Medicine, Fine chemical

Chris Cargill, President & CEO of Nxera Pharma, commented: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our Company’s journey.

Key Points: 
  • Chris Cargill, President & CEO of Nxera Pharma, commented: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our Company’s journey.
  • It follows the significant growth and development of the business, which has been accelerated through several key strategic acquisitions in recent years, including Heptares Therapeutics in 2015 and the Idorsia Pharmaceuticals Japan and Korea businesses in 2023.
  • “The Company decided that now is the optimal time to unify the business under a new name and bold brand.
  • I am extremely proud of what we have achieved since then and truly excited about what we, as Nxera Pharma, can deliver in the future, to our patients, partners, employees and shareholders, as this vision becomes a reality.

Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma

Retrieved on: 
Wednesday, March 27, 2024
Annual, EVP, Patient, Optimism, Change, Sosei, Fine chemical

Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held today in Tokyo.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held today in Tokyo.
  • In addition, the “Partial Amendment to the Articles of Incorporation (Change of Corporate Name)” was approved at the Annual Shareholder’s Meeting.
  • With this approval, the Company will change its name to Nxera Pharma Co., Ltd. with effect from 1 April 2024.
  • Shinichi Tamura, Chairman of Sosei Heptares, said: “2023 was a transformational year for Sosei Group enabling us to accelerate our development going forward as an integrated, technology powered, commercial-stage biopharmaceutical company focused on applying cutting-edge science to deliver life-changing medicines for patients in Japan and globally.

Close Brothers Goes Live with NETSOL's Cloud-Based Calculation Engine Flex

Retrieved on: 
Tuesday, March 26, 2024
Flex, Salesforce, NetSol Technologies, Ecosystem, API, Close Brothers Group, Fine chemical

ENCINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), the global leader in delivering state-of-the-art solutions for the asset finance and leasing industry, has announced that Close Brothers, a leading UK merchant banking group providing lending, deposit taking, wealth management services and securities trading, had signed-up for and has subsequently gone live with the Company’s calculation engine Flex.

Key Points: 
  • ENCINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), the global leader in delivering state-of-the-art solutions for the asset finance and leasing industry, has announced that Close Brothers, a leading UK merchant banking group providing lending, deposit taking, wealth management services and securities trading, had signed-up for and has subsequently gone live with the Company’s calculation engine Flex.
  • The Flex cloud-based calculation engine enables affordability checks, reverse calculations and accurate contract lifecycle calculations with seamless integration into a financial institution's ecosystem.
  • The calculation engine is part of NETSOL’s Appex Now suite of API-first products for the global finance and leasing industry.
  • These powerful, yet simple APIs are a reflection of our dedication to innovation,” said Najeeb Ghauri, Founder and CEO of NETSOL Technologies Inc.
    “Close Brothers joins other financial institutions in the United Kingdom that have gone live with our API-first calculation engine,” he added.

LogiPharma 2024 Playbook Highlights Why Real-Time Visibility & Data are Critical to Ensuring the Quality & Safety of New Medicines & Patient Therapies

Retrieved on: 
Tuesday, March 26, 2024
Automation, Temperature, Agility, Risk management, Research, Cold chain, Playbook, Johnson & Johnson, Artificial intelligence, Medtech, Fine chemical

The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.

Key Points: 
  • The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.
  • Guillen believes that ensuring the successful delivery and launch of dozens of new cell and gene therapies, as expected in 2024, is fundamentally dependent on the industry’s advancements in real-time supply chain visibility.
  • “An essential part of the conversation for pharma leaders today is how to address the critical challenges of modern therapy delivery," said Guillen.
  • To learn more about Tive and LogiPharma 2024, please visit www.tive.com and www.logipharmaeu.com .